Vaginal multipurpose prevention technologies: promising approaches for enhancing women’s sexual and reproductive health

References

• Glasier A, Gulmezoglu AM, Schmid GP, et al. Sexual and reproductive health: a matter of life and death. Lancet. 2006 Nov 4;368(9547):1595–1607.
   PubMed Web of Science ®Google Scholar
• UNAIDS. UNAIDS Data 2019. [cited 2019 Dec 3]. Available from: http://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data
   Google Scholar
• World Health Organization. Report on global sexually transmitted infection surveillance. 2018 [cited 2019 Dec 10]. Avaliable from: https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/
   Google Scholar
• Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019 Aug 1;97(8):548–62P.
   PubMed Web of Science ®Google Scholar
• GBD 2017. Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018 Nov 10;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• GBD 2017. Causes of death collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018 Nov 10;392(10159):1736–1788.
   PubMed Web of Science ®Google Scholar
• Bearak J, Popinchalk A, Alkema L, et al. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018 Apr;6(4):e380–e89.
   PubMed Web of Science ®Google Scholar
• Darroch JE, Singh S. Trends in contraceptive need and use in developing countries in 2003, 2008, and 2012: an analysis of national surveys. Lancet. 2013 May 18;381(9879):1756–1762.
   PubMed Web of Science ®Google Scholar
• Quaife M, Eakle R, Cabrera Escobar MA, et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Making. 2018;38(1):120–133.
   PubMed Web of Science ®Google Scholar
• Weinrib R, Minnis A, Agot K, et al. End-users’ product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South Africa. AIDS Behav. 2018 Jan;22(1):133–145.
   PubMed Web of Science ®Google Scholar
• Minnis AM, Browne EN, Boeri M, et al. Young women’s stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):394–403.
   PubMed Web of Science ®Google Scholar
• Hynes JS, Sheth AN, Lathrop E, et al. Preferred product attributes of potential multipurpose prevention technologies for unintended pregnancy and sexually transmitted infections or HIV among U.S. women. J Womens Health (Larchmt). 2019 May;28(5):665–672.
   PubMed Web of Science ®Google Scholar
• Quaife M, Terris-Prestholt F, Eakle R, et al. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018;21(3):Mar.
   Web of Science ®Google Scholar
• Population Council. Developing an oral contraceptive and HIV-prevention method, in a single pill. [cited 2019 Dec 12]. Available from: https://www.popcouncil.org/research/developing-an-oral-contraceptive-and-hiv-prevention-method-in-a-single-pill
   Google Scholar
• Rajoli R, Clark A, Rein-Weston A, et al. In silico design of a microarray patch as a multipurpose prevention technology [Abstract]. Rev Antivir Ther Infect Dis. 2019;4:4.
   Google Scholar
• RTI International. New multipurpose device to help prevent HIV and pregnancy. [cited 2019 Dec 6]. Available from: https://www.rti.org/news/new-multipurpose-device-help-prevent-hiv-and-pregnancy
   Google Scholar
• Clark JT, Clark MR, Shelke NB, et al. Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS One. 2014;9(3):e88509.
   PubMed Web of Science ®Google Scholar
• Dallal Bashi YH, McCoy CF, Murphy DJ, et al. Towards a dapivirine and levonorgestrel multipurpose vaginal ring: investigations into the reaction between levonorgestrel and addition-cure silicone elastomers. Int J Pharm. 2019 Oct;5(569):118574.
   Google Scholar
• Calenda G, Villegas G, Barnable P, et al. MZC gel inhibits SHIV-RT and HSV-2 in macaque vaginal mucosa and SHIV-RT in rectal mucosa. J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):e67–e74.
   PubMed Web of Science ®Google Scholar
• Brady M, Tolley E. Aligning product development and user perspectives: social-behavioural dimensions of multipurpose prevention technologies. BJOG. 2014 Oct;121(Suppl 5):70–78.
   PubMed Web of Science ®Google Scholar
• Barnhart KT, Izquierdo A, Pretorius ES, et al. Baseline dimensions of the human vagina. Hum Reprod. 2006 Jun;21(6):1618–1622.
   PubMed Web of Science ®Google Scholar
• Moore C, Daneshgari F. Vaginal anatomy for the pelvic surgeon. In: Zimmern PE, Norton PA, Haab F, et al., editors. Vaginal surgery for incontinence and prolapse. London: Springer; 2006. p. 3–10.
   Google Scholar
• Squier CA, Mantz MJ, Schlievert PM, et al. Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J Pharm Sci. 2008 Jan;97(1):9–21.
   PubMed Web of Science ®Google Scholar
• Richter K, Frick H. Anatomy of the visceral fascia of the pelvis from the didactic viewpoint [Article in German]. Geburtshilfe Frauenheilkd. 1985 May;45(5):282–287.
   PubMedGoogle Scholar
• Pendergrass PB, Reeves CA, Belovicz MW, et al. The shape and dimensions of the human vagina as seen in three-dimensional vinyl polysiloxane casts. Gynecol Obstet Invest. 1996;42(3):178–182.
   PubMed Web of Science ®Google Scholar
• das Neves J. Vaginal delivery of biopharmaceuticals. In: das Neves J, Sarmento B, editors. Mucosal delivery of biopharmaceuticals: biology, challenges and strategies. New York, NY: Springer; 2014. p. 261–280.
   Google Scholar
• Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011 Mar 15;108(Suppl 1):4680–4687.
   PubMed Web of Science ®Google Scholar
• das Neves J, Amiji M, Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 Jul 3;3(4):389–399.
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang YY, Hida K, et al. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):598–603.
   PubMed Web of Science ®Google Scholar
• Olmsted SS, Padgett JL, Yudin AI, et al. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J. 2001 Oct;81(4):1930–1937.
   PubMed Web of Science ®Google Scholar
• Boskey ER, Cone RA, Whaley KJ, et al. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod. 2001 Sep;16(9):1809–1813.
   PubMed Web of Science ®Google Scholar
• Farage M, Maibach H. Lifetime changes in the vulva and vagina. Arch Gynecol Obstet. 2006 Jan;273(4):195–202.
   PubMedGoogle Scholar
• Mwatelah R, McKinnon LR, Baxter C, et al. Mechanisms of sexually transmitted infection-induced inflammation in women: implications for HIV risk. J Int AIDS Soc. 2019 Aug;22(Suppl 6):e25346.
   PubMedGoogle Scholar
• Thurman AR, Doncel GF. Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. Am J Reprod Immunol. 2011 Feb;65(2):89–98.
   PubMed Web of Science ®Google Scholar
• das Neves J, Palmeira-de-Oliveira R, Palmeira-de-Oliveira A, et al. Vaginal mucosa and drug delivery. In: Khutoryanskiy VV, editor. Mucoadhesive materials and drug delivery systems. Chichester, UK: Wiley; 2014. p. 99–131.
   Google Scholar
• Blostein F, Levin-Sparenberg E, Wagner J, et al. Recurrent vulvovaginal candidiasis. Ann Epidemiol. 2017 Sep;27(9):575–82 e3.
   PubMed Web of Science ®Google Scholar
• Guirguis-Blake JM, Henderson JT, Perdue LA. Periodic screening pelvic examination: evidence report and systematic review for the US preventive services task force. JAMA. 2017 Mar 7;317(9):954–966.
   PubMed Web of Science ®Google Scholar
• Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release. 2005 Mar 21;103(2):301–313.
   PubMed Web of Science ®Google Scholar
• Woodsong C, Holt JD. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy. Adv Drug Deliv Rev. 2015 Feb 19;15(92):146–154.
   Google Scholar
• Hardy E, de Padua KS, Jimenez AL, et al. Women’s preferences for vaginal antimicrobial contraceptives. II. Preferred characteristics according to women’s age and socioeconomic status. Contraception. 1998 Oct;58(4):239–244.
   PubMed Web of Science ®Google Scholar
• Coggins C, Elias CJ, Atisook R, et al. Women’s preferences regarding the formulation of over-the-counter vaginal spermicides. AIDS. 1998 Jul 30;12(11):1389–1391.
   PubMed Web of Science ®Google Scholar
• Hardy E, de Padua KS, Osis MJ, et al. Women’s preferences for vaginal antimicrobial contraceptives. IV. Attributes of a formulation that would protect from STD/AIDS. Contraception. 1998 Oct;58(4):251–255.
   PubMed Web of Science ®Google Scholar
• Braunstein S. van de Wijgert J. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Womens Health. 2005 Jun;14(5):424–433.
   PubMed Web of Science ®Google Scholar
• Harrison PF, Hemmerling A, Romano J, et al. Developing multipurpose reproductive health technologies: an integrated strategy. AIDS Res Treat. 2013;2013:790154.
   PubMedGoogle Scholar
• Baeten JM, Hendrix CW, Hillier SL. Topical microbicides in HIV prevention: state of the promise. Annu Rev Med. 2019 Oct 15. DOI:10.1146/annurev-med-090518-3731.
   PubMed Web of Science ®Google Scholar
• Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990 Apr;80(4):460–462.
   PubMed Web of Science ®Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 3;329(5996):1168–1174.
   PubMed Web of Science ®Google Scholar
• Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018 Nov;18(11):1241–1250.
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015 Feb 5;372(6):509–518.
   PubMed Web of Science ®Google Scholar
• Malcolm RK, Boyd PJ, McCoy CF, et al. Microbicide vaginal rings: technological challenges and clinical development. Adv Drug Deliv Rev. 2016 Aug;1(103):33–56.
   Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016 Dec;375(22):2121–2132.
   PubMed Web of Science ®Google Scholar
• Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016 Dec;375(22):2133–2143.
   PubMed Web of Science ®Google Scholar
• Romano J, Manning J, Hemmerling A, et al. Prioritizing multipurpose prevention technology development and investments using a target product profile. Antiviral Res. 2013 Dec;100(Suppl):S32–8.
   PubMedGoogle Scholar
• van de Wijgert JH, Morrison CS, Brown J, et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African women. Sex Transm Dis. 2009 Jun;36(6):357–364.
   PubMed Web of Science ®Google Scholar
• van de Wijgert JH, Chirenje ZM, Iliff V, et al. Effect of intravaginal practices on the vaginal and cervical mucosa of Zimbabwean women. J Acquir Immune Defic Syndr. 2000 May 1;24(1):62–67.
   PubMed Web of Science ®Google Scholar
• Van Der Pol B, Kwok C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis. 2008 Feb 15;197(4):548–554.
   PubMed Web of Science ®Google Scholar
• Higgins JA, Smith NK, Sanders SA, et al. Dual method use at last sexual encounter: a nationally representative, episode-level analysis of US men and women. Contraception. 2014 Oct;90(4):399–406.
   PubMed Web of Science ®Google Scholar
• Podaralla S, Alt C, Shankar GN. Formulation development and evaluation of innovative two-polymer (SR-2P) bioadhesive vaginal gel. AAPS PharmSciTech. 2014 Aug;15(4):928–938.
   PubMed Web of Science ®Google Scholar
• Ugaonkar SR, Wesenberg A, Wilk J, et al. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy. J Control Release. 2015 Sep 10;213:57–68.
   PubMed Web of Science ®Google Scholar
• Smith JM, Moss JA, Srinivasan P, et al. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: pharmacokinetic evaluation in a macaque model. PLoS One. 2017;12(10):e0185946.
   PubMed Web of Science ®Google Scholar
• CONRAD. Safety, PK, and PD study of a vaginal insert containing TAF and EVG. Available from: https://clinicaltrials.gov/ct2/show/NCT03762772
   Google Scholar
• LeafBio I Vaginal antibody safety trial: safety study of monoclonal antibodies to reduce the vaginal transmission of herpes simplex virus (HSV) and human immunodeficiency virus (HIV). Available from: https://clinicaltrials.gov/ct2/show/NCT02579083
   Google Scholar
• Population Council. Safety, pharmacokinetics and acceptability of PC-1005 for vaginal use. Available from: https://clinicaltrials.gov/ct2/show/NCT02033109
   Google Scholar
• Price CF, Tyssen D, Sonza S, et al. SPL7013 gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One. 2011;6(9):e24095.
   PubMed Web of Science ®Google Scholar
• CONRAD. Safety and effectiveness of tenofovir gel in the prevention of human immunodeficiency virus (HIV-1) infection in women and the effects of tenofovir gel on the incidence of herpes simplex virus (HSV-2) infection. Available from: https://clinicaltrials.gov/ct2/show/NCT01386294
   Google Scholar
• Pazol K, Kramer MR, Hogue CJ. Condoms for dual protection: patterns of use with highly effective contraceptive methods. 433021. 2010 Mar-Apr;125(2):208–217.
   Google Scholar
• Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect. 1999 Nov-Dec;31(6):272–279.
   PubMedGoogle Scholar
• Gallo MF, Grimes DA, Lopez LM, et al. Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev. 2006 Jan;25(1):CD003550.
   Google Scholar
• Friend DR, Doncel GF. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies. Antiviral Res. 2010 Dec;88(Suppl 1):S47–54.
   PubMedGoogle Scholar
• Major I, Boyd P, Kilbourne-Brook M, et al. A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine. Contraception. 2013;88(1):58–66.
   PubMed Web of Science ®Google Scholar
• Mohammed Fayaz A, Ao Z, Girilal M, et al. Inactivation of microbial infectiousness by silver nanoparticles-coated condom: a new approach to inhibit HIV- and HSV-transmitted infection. Int J Nanomedicine. 2012;7:5007–5018.
   PubMed Web of Science ®Google Scholar
• Frezieres RG, Walsh T, Kilbourne-Brook M, et al. Couples’ acceptability of the SILCS diaphragm for microbicide delivery. Contraception. 2012 Jan;85(1):99–107.
   PubMed Web of Science ®Google Scholar
• Giguere R, Carballo-Dieguez A, Ventuneac A, et al. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico. Cult Health Sex. 2012;14(2):151–166.
   PubMed Web of Science ®Google Scholar
• Gali Y, Delezay O, Brouwers J, et al. In vitro evaluation of viability, integrity and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob Agents Chemother. 2010 Oct 4;54(12):5105–5114.
   PubMed Web of Science ®Google Scholar
• Fernández-Romero JA, Teleshova N, Zydowsky TM, et al. Preclinical assessments of vaginal microbicide candidate safety and efficacy. Adv Drug Deliv Rev. 2015 Sep;15(92):27–38.
   Google Scholar
• Veazey RS. Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr Opin HIV AIDS. 2008 Sep;3(5):567–573.
   PubMed Web of Science ®Google Scholar
• Veazey RS, Shattock RJ, Klasse PJ, et al. Animal models for microbicide studies. Curr HIV Res. 2012 Jan 1;10(1):79–87.
   PubMed Web of Science ®Google Scholar
• Kizima L, Rodriguez A, Kenney J, et al. A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV. PLoS One. 2014;9(4):e94547.
   PubMed Web of Science ®Google Scholar
• Fichorova RN, Bajpai M, Chandra N, et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod. 2004 Sep;71(3):761–769.
   PubMed Web of Science ®Google Scholar
• Moss JA, Malone AM, Smith TJ, et al. Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model. Antimicrob Agents Chemother. 2013 Aug;57(8):3994–3997.
   PubMed Web of Science ®Google Scholar
• Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992 Jul 22–29;268(4):477–482.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002 Sep 28;360(9338):971–977.
   PubMed Web of Science ®Google Scholar
• Thurman AR, Schwartz JL, Brache V, et al. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PLoS One. 2018;13(6):e0199778.
   PubMed Web of Science ®Google Scholar
• Achilles SL, Hendrix CW, Poloyac SM, et al. Safety and pharmacokinetics of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy [Abstract]. AIDS Res Hum Retroviruses. 2018;34(S1):46.
   PubMedGoogle Scholar
• Lanham M, Wilcher R, Montgomery ET, et al. Engaging male partners in women’s microbicide use: evidence from clinical trials and implications for future research and microbicide introduction. J Int AIDS Soc. 2014;17(3 Suppl 2):19159.
   PubMedGoogle Scholar
• Walwyn D, Maitshotlo B. Perspectives of traditional health practitioners on the use of microbicides for the prevention of HIV. Afr J Tradit Complement Altern Med. 2012;9(3 Suppl):24–26.
   PubMedGoogle Scholar
• van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One. 2014;9(2):e89118.
   PubMed Web of Science ®Google Scholar
• Hoffman S, Morrow KM, Mantell JE, et al. Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. women in a vaginal microbicide clinical trial. Arch Sex Behav. 2010 Jun;39(3):748–760.
   PubMed Web of Science ®Google Scholar
• Montgomery ET, van der Straten A, Chidanyika A, et al. The importance of male partner involvement for women’s acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2011 Jul;15(5):959–969.
   PubMed Web of Science ®Google Scholar
• Mngadi KT, Maarschalk S, Grobler AC, et al. Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav. 2014 May;18(5):849–854.
   PubMed Web of Science ®Google Scholar
• Friend DR. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission. Expert Opin Drug Deliv. 2012 Apr;9(4):417–427.
   PubMed Web of Science ®Google Scholar
• Friend DR, Clark JT, Kiser PF, et al. Multipurpose prevention technologies: products in development. Antiviral Res. 2013 Dec;100(Suppl):S39–47.
   PubMedGoogle Scholar
• Friend DR. An update on multipurpose prevention technologies for the prevention of HIV transmission and pregnancy. Expert Opin Drug Deliv. 2016;13(4):533–545.
   PubMed Web of Science ®Google Scholar
• Fernández-Romero JA, Deal C, Herold BC, et al. Multipurpose prevention technologies: the future of HIV and STI protection. Trends Microbiol. 2015 Jul;23(7):429–436.
   PubMed Web of Science ®Google Scholar
• Woodsong C, Holt J, Devlin B, et al. Current status of multipurpose prevention technology (MPT) development. Curr Obstet Gynecol Rep. 2015;4(1):43–52.
   Web of Science ®Google Scholar
• Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev. 2005 Nov 3;57(11):1692–1712.
   PubMed Web of Science ®Google Scholar
• McConville C, Major I, Devlin B, et al. Development of a multi-layered vaginal tablet containing dapivirine, levonorgestrel and acyclovir for use as a multipurpose prevention technology. Eur J Pharm Biopharm. 2016 Jul;104:171–179.
   PubMed Web of Science ®Google Scholar
• Lal M, Lai M, Ugaonkar S, et al. Development of a vaginal fast-dissolving insert combining griffithsin and carrageenan for potential use against sexually transmitted infections. J Pharm Sci. 2018 Oct;107(10):2601–2610.
   PubMed Web of Science ®Google Scholar
• Levendosky K, Mizenina O, Martinelli E, et al. Griffithsin and carrageenan combination to target herpes simplex virus 2 and human papillomavirus. Antimicrob Agents Chemother. 2015 Dec;59(12):7290–7298.
   PubMed Web of Science ®Google Scholar
• Nader-Macías ME, Juárez Tomás MS. Profiles and technological requirements of urogenital probiotics. Adv Drug Deliv Rev. 2015 Sep;15(92):84–104.
   Google Scholar
• Sánchez MT, Ruiz MA, Castán H, et al. A novel double-layer mucoadhesive tablet containing probiotic strain for vaginal administration: design, development and technological evaluation. Eur J Pharm Sci. 2018 Jan;15(112):63–70.
   Google Scholar
• Machado RM, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, et al. Vaginal films for drug delivery. J Pharm Sci. 2013 May 6;102(7):2069–2081.
   PubMed Web of Science ®Google Scholar
• Cautela MP, Moshe H, Sosnik A, et al. Composite films for vaginal delivery of tenofovir disoproxil fumarate and emtricitabine. Eur J Pharm Biopharm. 2019 2;Feb(138):3–10.
   Google Scholar
• Cunha-Reis C, Machado A, Barreiros L, et al. Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs. J Control Release. 2016 Sep;21(243):43–53.
   Web of Science ®Google Scholar
• Griffin JB, Ridgeway K, Montgomery E, et al. Vaginal ring acceptability and related preferences among women in low- and middle-income countries: a systematic review and narrative synthesis. PLoS One. 2019;14(11):e0224898.
   PubMed Web of Science ®Google Scholar
• Johnson TJ, Gupta KM, Fabian J, et al. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci. 2010 Feb 19;39(4):203–212.
   PubMed Web of Science ®Google Scholar
• Boyd P, Fetherston SM, McCoy CF, et al. Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel. Int J Pharm. 2016 Sep 10;511(1):619–629.
   PubMed Web of Science ®Google Scholar
• Moss JA, Malone AM, Smith TJ, et al. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother. 2012 Feb;56(2):875–882.
   PubMed Web of Science ®Google Scholar
• das Neves J, Bahia MF. Gels as vaginal drug delivery systems. Int J Pharm. 2006 Aug 2;318(1–2):1–14.
   PubMedGoogle Scholar
• Guthrie KM, Dunsiger S, Vargas SE, et al. Perceptibility and the “choice experience”: user sensory perceptions and experiences inform vaginal prevention product design. AIDS Res Hum Retroviruses. 2016;32(10–11):1022–1030.
   PubMed Web of Science ®Google Scholar
• Duby Z, Mensch B, Hartmann M, et al. Achieving the optimal vaginal state: using vaginal products and study gels in Uganda, Zimbabwe, and South Africa. Int J Sex Health. 2017;29(3):247–257.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Abdool Karim Q, Kharsany AB, et al. Tenofovir gel for the prevention of herpes simplex virus type 2 infection. N Engl J Med. 2015 Aug 6;373(6):530–539.
   PubMed Web of Science ®Google Scholar
• Friedland BA, Hoesley CJ, Plagianos M, et al. First-in-human trial of MIV-150 and zinc acetate coformulated in a carrageenan gel: safety, pharmacokinetics, acceptability, adherence, and pharmacodynamics. J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):489–496.
   PubMed Web of Science ®Google Scholar
• Nelson AL. An overview of properties of Amphora (Acidform) contraceptive vaginal gel. Expert Opin Drug Saf. 2018 Sep;17(9):935–943.
   PubMed Web of Science ®Google Scholar
• Wang L, Sassi AB, Patton D, et al. Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention. Drug Dev Ind Pharm. 2012 Aug;38(8):995–1007.
   PubMed Web of Science ®Google Scholar
• Lakshmi YS, Kumar P, Kishore G, et al. Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles. Sci Rep. 2016 May;6(6):25479.
   PubMedGoogle Scholar
• Lazniewska J, Milowska K, Gabryelak T. Dendrimers – revolutionary drugs for infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012 Sep-Oct;4(5):469–491.
   PubMed Web of Science ®Google Scholar
• McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm. 2005 Jul-Aug;2(4):312–318.
   PubMedGoogle Scholar
• McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS. 2011 May 15;25(8):1057–1064.
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Kaul R, Ma Y, et al. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):134–140.
   PubMed Web of Science ®Google Scholar
• Sepúlveda-Crespo D, Ceña-Díez R, Jiménez JL, et al. Mechanistic studies of viral entry: an overview of dendrimer-based microbicides as entry inhibitors against both HIV and HSV-2 overlapped infections. Med Res Rev. 2017 Aug 12;37(1):149–179.
   PubMed Web of Science ®Google Scholar
• Cena-Diez R, Martin-Moreno A, de la Mata FJ, et al. G1-S4 or G2-S16 carbosilane dendrimer in combination with Platycodin D as a promising vaginal microbicide candidate with contraceptive activity. Int J Nanomedicine. 2019;14:2371–2381.
   PubMed Web of Science ®Google Scholar
• Laborde ND, Leslie J, Krogstad E, et al. Perceptions of the “Fabric” – an exploratory study of a novel multi-purpose technology among women in Sub Saharan Africa. PLoS One. 2018;13(10):e0204821.
   PubMed Web of Science ®Google Scholar
• Blakney AK, Krogstad EA, Jiang YH, et al. Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Int J Nanomedicine. 2014;9:2967–2978.
   PubMed Web of Science ®Google Scholar
• Chou SF, Carson D, Woodrow KA. Current strategies for sustaining drug release from electrospun nanofibers. J Control Release. 2015 Dec 28;220(Pt B):584–591.
   PubMedGoogle Scholar
• Ball C, Krogstad E, Chaowanachan T, et al. Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS One. 2012;7(11):e49792.
   PubMed Web of Science ®Google Scholar
• Tyo KM, Vuong HR, Malik DA, et al. Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro. Int J Pharm. 2017 Oct 5;531(1):118–133.
   PubMedGoogle Scholar
• Alukda D, Sturgis T, Youan BB. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J Pharm Sci. 2011 Aug;100(8):3345–3356.
   PubMed Web of Science ®Google Scholar
• Zhang T, Sturgis TF, Youan BB. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm. 2011 Nov;79(3):526–536.
   PubMed Web of Science ®Google Scholar
• Tevi-Benissan C, Belec L, Levy M, et al. In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol. 1997 May;4(3):367–374.
   PubMedGoogle Scholar
• Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, et al. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology. 2010;8:1.
   PubMedGoogle Scholar
• Vijayakumar S, Ganesan S. Gold nanoparticles as an HIV entry inhibitor. Curr HIV Res. 2012 Dec;10(8):643–646.
   PubMed Web of Science ®Google Scholar
• Baram-Pinto D, Shukla S, Gedanken A, et al. Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. Small. 2010 May 7;6(9):1044–1050.
   PubMed Web of Science ®Google Scholar
• Etemadzade M, Ghamarypour A, Zabihollahi R, et al. Synthesis and evaluation of antiviral activities of novel sonochemical silver nanorods against HIV and HSV viruses. Asian Pacific J Trop Dis. 2016;6(11):854–858.
   Google Scholar
• U.S. Food & Drug Administration. Guidance for industry. vaginal microbicides: development for the prevention of HIV infection. Silver Spring, MD; 2014 [cited 2019 Feb 15]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm328842.pdf
   Google Scholar
• U.S. Food and Drug Administration. Guidance for the development of vaginal contraceptive drugs (NDA). Silver Spring, MD; 1998[cited 2019 Feb 15]. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-development-vaginal-contraceptive-drugs-nda
   Google Scholar
• Kis O, Robillard K, Chan GN, et al. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2010 Jan;31(1):22–35.
   PubMed Web of Science ®Google Scholar
• Nardi R, Arterburn L, Carlton L. Developing regulatory strategy for microbicides. Curr Top Microbiol Immunol. 2014;383:137–152.
   PubMed Web of Science ®Google Scholar
• Steytner J What’s next in the dapivirine ring licensure program? MTN 2019 Regional Meeting, Cape Town, South Africa. [cited 2019 Dec 10]. Available from: https://mtnstopshiv.org/sites/default/files/steytler-mtn_meeting_presentation_1.0_09_sep2019.pdf
   Google Scholar